Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1169.34 | +3.4% | 1.5M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.5t | $232.12 | -0.3% | 1.5M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $384.7b | $224.26 | -1.3% | 1.2M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $293.2b | $120.91 | +0.1% | 2.3M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $287.9b | $183.90 | -1.1% | 630.7K |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $181.8b | $346.84 | -0.8% | 440.9K |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $166.9b | $128.72 | -0.3% | 1.4M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $116.8b | $56.84 | -0.7% | 2.5M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $64.5b | $623.11 | -1.9% | 125.9K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $33.5b | $149.69 | +0.3% | 621.9K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $32.0b | $216.48 | +0.5% | 192.0K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $24.7b | $55.84 | -0.1% | 990.5K |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $19.3b | $101.58 | -0.8% | 767.3K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $18.7b | $48.44 | +2.1% | 1.0M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $17.2b | $128.29 | +2.1% | 350.3K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $14.8b | $237.04 | -0.6% | 122.8K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $12.7b | $52.48 | -0.4% | 257.1K |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $8.7b | $89.44 | -1.7% | 213.0K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.9b | $71.27 | -0.4% | 381.4K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.9b | $7.06 | +2.1% | 3.9M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $7.5b | $74.78 | +3.0% | 157.0K |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.5b | $88.75 | +0.5% | 282.6K |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $101.19 | +0.2% | 128.1K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.0b | $31.55 | +1.7% | 323.8K |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.5b | $53.67 | -0.1% | 101.0K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.7b | $16.74 | +1.5% | 577.1K |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $4.6b | $98.35 | +1.2% | 196.7K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.0b | $12.56 | +4.9% | 1.8M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.7b | $48.60 | -0.3% | 290.6K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.2b | $23.59 | +1.7% | 180.7K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.2b | $26.65 | +31.8% | 9.6M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $3.1b | $59.91 | -0.1% | 142.9K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.1b | $13.95 | +3.1% | 541.9K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $29.77 | +5.2% | 293.7K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.5b | $34.30 | -1.2% | 162.3K |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.5b | $18.54 | -0.2% | 135.5K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.4b | $17.27 | +2.2% | 503.5K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.2b | $56.13 | -2.1% | 231.0K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.0b | $26.56 | -0.3% | 197.1K |
 NVCR | NovoCure Limited Ordinary Shares | Targeted Therapy & Precision Oncology | $2.0b | $17.57 | +2.4% | 227.6K |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $2.0b | $13.59 | +0.3% | 988.7K |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $1.9b | $5.58 | -0.6% | 1.3M |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $24.10 | +0.3% | 105.7K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.8b | $16.17 | +10.5% | 13.3M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.8b | $4.11 | -3.0% | 3.1M |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $1.7b | $17.05 | -1.7% | 563.1K |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $1.7b | $8.26 | +0.4% | 2.2M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $16.28 | -0.6% | 549.2K |